Sorry, you need to enable JavaScript to visit this website.
THIS CONTENT HAS BEEN ARCHIVED

144th session of the WHO Executive Board - EU Statement - Item 5.7 – Access to medicines, vaccines and health products

26.01.2019
Teaser

144th session of the WHO Executive Board
Geneva, 24 January – 1 February 2019
EU Statement - Item 5.7 – Access to medicines, vaccines and health products

Text

Madam Chair,

Distinguished Director-General,

Colleagues,

I am speaking on behalf of the EU and its Member States.

The Candidate Countries Montenegro[*], Serbia* and Albania*, the country of the Stabilisation and Association Process and potential candidate Bosnia and Herzegovina, as well as Ukraine, the Republic of Moldova and Georgia align themselves with this statement.

We thank WHO for the draft roadmap which is fully aligned with WHO role and mandate and which we deem very useful for WHO and MS.

Access to medicines, vaccines and health products is today a concern for all countries. High prices, poor quality, including substandard and falsified health products, can threaten the sustainability of health systems and affect vulnerable populations, in particular in LDCs and fragile states, and lead to the further development of antimicrobial resistance.

Universal access to medicines is not only a fundamental element for the realization of the human right to the enjoyment of the highest attainable standard of physical and mental health and a prerequisite for effective universal health coverage. Promoting access to essential medicines is also our ethical responsibility and part of the SDGs. Therefore health system reforms should integrate coverage of medicines, vaccines and health products into solidarity UHC financial protection mechanisms, whereby domestic financing is key.

WHO has a key role to play in building universal access to essential safe, effective, quality-assured and affordable medicines: this role is both normative and technical, for instance through assistance to National Regulatory Authorities in order to strengthen their pharmaceutical policies and strategies, through a health systems and human rights approach.

We stress in this regard the importance of a whole systems (holistic) approach on the entire value chain of access to medicines, including good governance, transparency and synergies, fair pricing, adequate regulatory and workforce capacity, and more efficient supply chains. We repeat our proposal on continuing the exchange of views on these matters in upcoming WHAs.

We welcome the work of WHO to develop an agreed list of indicators which will contribute to the measurement of an SDG indicator on access to medicines and improve existing accountability mechanisms regarding monitoring and data.

As to the proposed road map, we would welcome greater clarity on how the actions and deliverables in each strategic area link to the milestones, in particular with respect to timing and would like to see a budget allocated against these actions and deliverables.

It has to be recognized that the lack of access to medicines cannot simply be attributed to a market failure but needs wider effective policy debate and interventions on the part of both donor and recipient countries.

New and innovative approaches on access to medicines are needed.

We would like more detail on WHO’s commitment to develop incentive and delinkage mechanisms for new product development, including the scope and timing of these activities. In this regard, we would urge WHO to include a commitment on equitable access and appropriate stewardship of new drugs.

Quality of medicines, the strengthening of health systems and fair pricing, should be amongst the strategic priorities of WHO, and be allocated appropriate resources. In this respect, we recognize the WHO Prequalification Programme as a global public good.

Access to quality-assured medicines and their appropriate use, as well as stewardship and surveillance measures, are equally important to tackle AMR, which poses a threat to the effectiveness of medicines, the achievement of the SDGs and UHC if not addressed appropriately. In this regard we refer to the WHO-AWARE list.

In conclusion, the use and access to quality and affordable essential medicines go hand in hand and should be universal, available everywhere and for everyone. The end-user and patient should be at the center, in order to contribute to sustainability and ownership.

Thank you.

 

[*] Montenegro, Serbia and Albania continue to be part of the Stabilisation and Association Process.

 

Category
Statements on behalf of the EU
Location

Geneva

Editorial sections
UN Geneva